Aetna Loses Bid To Re-Enter Pfizer Off-Label MDL
A Massachusetts judge on Wednesday refused to reconsider Aetna Inc.'s suit accusing Pfizer Inc. of improperly marketing the epilepsy drug Neurontin in violation of racketeering and competition laws....To view the full article, register now.
Already a subscriber? Click here to view full article